Citeline Podcasts

Davinderpreet Mangat and Shardha Millington discuss the current and future role of long-acting agents in HIV treatment and PrEP.

Topics covered include:

HIV treatment – 4:30

HIV PrEP – 22:45

Supporting links:

https://service.datamonitorhealthcare.com/hkc/disease/infectious-diseases/viral-infections/hiv-pre-exposure-prophylaxis-hiv-prep/disease-analysis/article225313.ece

https://service.datamonitorhealthcare.com/hkc/disease/infectious-diseases/viral-infections/human-immunodeficiency-virus/disease-analysis/article225293.ece

Other platforms:

Apple Podcasts -   https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836

Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zb3VuZGNsb3VkLmNvbS91c2Vycy9zb3VuZGNsb3VkOnVzZXJzOjEwNjU1NDkyOC9zb3VuZHMucnNz

TuneIn - https://tunein.com/podcasts/Business--Economics-Podcasts/Pharma-Intelligence-Podcasts-p1140128/

Spotify Podcasts - https://open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67

Scrip’s Five Must-Know Things – 18 October 2021 by Citeline

In this week’s podcast, EU regulatory editor Amanda Maxwell brings listeners up to speed on the latest news from the European Union. Topics include discussion of ISO 13485, ongoing industry concerns with MDR implementation, and the Eudamed database expansion.

In this month’s podcast, Medtech Insight's Reed Miller and Marion Webb provide a recap of our digital health coverage in August and September, including start-ups that grabbed new funding, news from AAOS 2021 and regulatory news.

Medtech Insight articles addressing topics discussed in this episode:

Akili Pays $37.5M To License Tali’s Tech For Early Childhood Attention Impairments

https://medtech.pharmaintelligence.informa.com/MT144365/Akili-Pays-375M-To-License-Talis-Tech-For-Early-Childhood-Attention-Impairments

Hagar Lands Funding To Develop Noninvasive Glucose Monitoring Watch

https://medtech.pharmaintelligence.informa.com/MT144335/Hagar-Lands-Funding-To-Develop-Noninvasive-Glucose-Monitoring-Watch

Flywheel.io Raises $22M And Buys Out Competition

https://medtech.pharmaintelligence.informa.com/MT144463/Flywheelio-Raises-22M-And-Buys-Out-Competition

Zoll Medical Signs Definite Agreement To Buy Itamar Medical For $538M

https://medtech.pharmaintelligence.informa.com/MT144453/Zoll-Medical-Signs-Definite-Agreement-To-Buy-Itamar-Medical-For-$538M

A Closer Look At Think Surgical’s Active Open Implant Orthopedic Robot and What’s Ahead

https://medtech.pharmaintelligence.informa.com/MT144506/AAOS-2021-A-Closer-Look-At-Think-Surgicals-Active-OpenImplant-Orthopedic-Robot-And-Whats-Ahead

Zimmer Biomet Canary Medical Win FDA De Novo For First Smart Knee Implant

https://medtech.pharmaintelligence.informa.com/MT144400/Zimmer-Biomet-Canary-Medical-Win-FDA-De-Novo-For-First-Smart-Knee-Implant

Exec Chat: AAOS 2021 Outgoing President Bosco Discusses Hot-Button-Issues – Inpatient-Only List, Pre-Authorization, New Tech

https://medtech.pharmaintelligence.informa.com/MT144412/Exec-Chat-AAOS-2021-Outgoing-President-Bosco-Discusses-HotButton-Issues--InpatientOnly-List-PreAuthorization-New-Tech

Market Intel: Robotic Surgery Holds Great Promise, But Is Not Quite There Yet

https://medtech.pharmaintelligence.informa.com/MT144388/Market-Intel-Robotic-Surgery-Holds-Great-Promise-But-Is-Not-Quite-There-Yet

New FDA Web Page Spotlights AI/ML Progress

https://medtech.pharmaintelligence.informa.com/MT144493/New-FDA-Web-Page-Spotlights-AIML-Progress

MDIC Digital Health Initiative Could Be Crucial To FDA Pre-Cert Program

https://medtech.pharmaintelligence.informa.com/MT144390/MDIC-Digital-Health-Initiative-Could-Be-Crucial-To-FDA-Pre-Cert-Program

FDA Greenlights First-Of-Its-Kind Heart Software

https://medtech.pharmaintelligence.informa.com/MT144454/FDA-Greenlights-First-Of-Its-Kind-Heart-Software

Another Set Of Eyes: US FDA Authorizes AI Software To Spot Prostate Cancer

https://medtech.pharmaintelligence.informa.com/MT144487/Another-Set-Of-Eyes-US-FDA-Authorizes-AI-Software-To-Spot-Prostate-Cancer

Expert: AI/ML Pediatric Software Brings Hope – But Also Potential – To Magnifying Disparities

https://medtech.pharmaintelligence.informa.com/MT144425/Expert-AIML-Pediatric-Software-Brings-Hope--But-Also-Potential--To-Magnifying-Disparities

FDA Panel Meeting To Focus On AI/ML Device Labeling, Transparency

https://medtech.pharmaintelligence.informa.com/MT144379/FDA-Panel-Meeting-To-Focus-On-AIML-Device-Labeling-Transparency

Congress Marks First Telehealth Awareness Week

https://medtech.pharmaintelligence.informa.com/MT144501/Congress-Marks-First-Telehealth-Awareness-Week

For more information on Medtech Insight and to start a free trial, click here:

http://bit.ly/2w7LnlR

Scrip’s Five Must-Know Things – 11 October 2021 by Citeline

Pink Sheet editor and reporters discuss the impact of Francis Collins’ departure as NIH director, whether FDA and CDC COVID-19 messaging should be harmonized, and the narrowing gap between standard and priority assessment costs.

Device Week, Oct. 08, 2021 – Boston Scientific Acquisition, And Poor SPAC Float

In this edition of Device Week, Medtech Insight’s Reed Miller discusses Boston Scientific’s acquisition of Baylis, and what it means for its heart business. UK-based reporter Barnaby Pickering looks into LumiraDX’s recent float on the stock market, and why it might have been so poorly received.

Medtech Insight articles addressing topics discussed in this episode:

- Boston Scientific Continues Acquisition Streak With $1.75Bn Deal For Baylis’ Cardiology Products

- LumiraDX Goes Public In SPAC Merger

Canadian biotech Providence Therapeutics CEO talks to Scrip on mRNA vaccines against COVID-19, cancer

Shownotes – Providence Therapeutics CEO Brad Sorenson talks about his company’s plans for Phase II, III clinical trials for an mRNA vaccine as well as marketing and manufacturing partnerships with Biological E, Everest Medicines, Emergent Biosolutions and Northern RNA. He also discusses Providence’s m-RNA vaccines against cancer

In the inaugural episode of our new deep-dive podcast Speaking Of Medtech, former US FDA device center compliance chief Steve Silverman and Medtech Insight executive editor Shawn M. Schmitt discuss remote facility inspections and question whether they’re the wave of the future.

Medtech Insight articles addressing topics discussed in this episode:

• Come On In, The Water’s Fine: FDA Should Fully Embrace Remote Inspections

https://medtech.pharmaintelligence.informa.com/MT144289/Come-On-In-The-Waters-Fine-FDA-Should-Fully-Embrace-Remote-Inspections

• Enforcement Comeback? FDA Predicts 1,767% Increase In US Inspections In FY ’22, Matching Pre-Pandemic Levels

https://medtech.pharmaintelligence.informa.com/MT143997/Enforcement-Comeback-FDA-Predicts-1767-Increase-In-US-Inspections-In-FY-22-Matching-PrePandemic-Levels

• To RRA, Or Not To RRA? BD Talks Decision-Making Around FDA Requests For Remote Regulatory Assessments

https://medtech.pharmaintelligence.informa.com/MT144053/To-RRA-Or-Not-To-RRA-BD-Talks-DecisionMaking-Around-FDA-Requests-For-Remote-Regulatory-Assessments

• ‘We Were A Victim’: How An FDA Remote Regulatory Assessment Took One Device Maker By Surprise

https://medtech.pharmaintelligence.informa.com/MT143998/We-Were-A-Victim-How-An-FDA-Remote-Regulatory-Assessment-Took-One-Device-Maker-By-Surprise

Announcing The Inaugural Informa Pharma Intelligence Awards Japan 2022 by Citeline